<DOC>
	<DOCNO>NCT00509041</DOCNO>
	<brief_summary>RATIONALE : Dasatinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well dasatinib work treat patient previously treat malignant mesothelioma .</brief_summary>
	<brief_title>Dasatinib Treating Patients With Previously Treated Malignant Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine rate progression-free survival ( PFS ) 24 week ( 5.5 month ) patient malignant mesothelioma treat dasatinib . Secondary - To determine response rate ( partial response [ PR ] complete response [ CR ] ) patient malignant mesothelioma treat dasatinib . - To determine response duration patient malignant mesothelioma treat dasatinib . - To describe overall survival ( OS ) patient malignant mesothelioma treat dasatinib . - To describe toxicity profile dasatinib patient malignant mesothelioma . - To determine whether amount expression EphA2 PDGFRβ , measure immunohistochemistry tumor specimen , correlate PFS patient malignant mesothelioma . - To determine whether plasma level VEGF PDGFRβ , serum level CSF-1 , soluble mesothelin-related protein correlate PFS patient malignant mesothelioma . - To determine whether inhibition Src phosphorylation PBMC correlate PFS . - To assess inhibition phosphorylation Src , EphA2 , PDGFRβ tumor tissue dasatinib . OUTLINE : Patients receive oral dasatinib twice daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo tumor tissue blood sample collection periodically correlative study . Tumor tissue sample analyze EphA2 PDGFRβ expression immunohistochemistry . Tumor tissue sample may also analyze phosphorylation Src , EphA2 , PDGFRβ western blot . Blood sample analyze concentration VEGF PDGF quantitative sandwich enzyme immunoassay technique ; mesothelin-related protein level Mesomark® assay ; CSF-1 level ELISA assay ; phosphorylation Src phospho-Src ( pTyr418 ) human ELISA . After completion study treatment , patient follow least every 2 month 1 year , every 4 month 1 year , every 6 month 1 year .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant mesothelioma follow subtypes : Epithelial Sarcomatoid Mixed Any site origin malignant mesothelioma allow include , limited , follow : Pleura Peritoneum Pericardium Tunica vaginalis Pathology block slide core surgical biopsy must available Not amenable curative surgery Measurable disease , define lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ( CT scan , MRI , xray ) ≥ 10 mm spiral CT scan Patients pleural rind disease must least one level one rind measurement ≥ 1.5 cm Lesions consider nonmeasurable include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Prior treatment one one systemic chemotherapy regimen , must include pemetrexed disodium require Treatment may pemetrexed disodium alone combination agent No symptomatic pleural effusion , unless patient undergoes therapeutic thoracentesis Patients pleural effusion pleurodesis eligible No known brain metastasis May register CALGB150707 companion study PATIENT CHARACTERISTICS : ECOG performance status 01 Granulocytes ≥ 1,500/μL Platelet count ≥ 100,000/μL Total bilirubin ≤ 2 x upper limit normal ( ULN ) AST ( SGOT ) ≤ 2.5 x ULN Creatinine clearance ≥ 60 mL/min INR &lt; 1.5 PTT &lt; 40 second QTc &lt; 450 msec Not pregnant nursing Fertile patient must use effective contraception No significant cardiac disease , include follow : New York Heart Association ( NYHA ) class IIIIV congestive heart failure ( CHF ) Unstable angina Myocardial infarction ventricular tachyarrhythmia within 6 month study entry Ejection fraction less institutional normal ( patient history CHF currently NYHA class I II CHF ) Prolonged QTc &gt; 450 msec ( Fridericia correction ) Major conduction abnormality , unless cardiac pacemaker present Hypokalemia hypomagnesemia correct No history significant bleeding disorder unrelated cancer , include follow : Congenital bleeding disorder ( e.g. , von Willebrand disease ) Acquired bleed disorder within past year ( e.g. , acquire antifactor VIII antibody ) Ongoing recent ( ≤ 3 month ) significant GI bleed hemoptysis No requirement supplemental oxygen ( i.e. , pulse oximetry &lt; 89 % rest ) PRIOR CONCURRENT THERAPY : At least 4 week since prior pemetrexed disodiumcontaining chemotherapy At least 4 week since prior major surgery At least 4 week since prior radiation therapy Measurable disease must outside radiation port Prior intracavitary cytotoxic sclerosing therapy ( include bleomycin ) allow Intrapleural cytotoxic chemotherapy consider systemic chemotherapy At least 7 day since prior concurrent antithrombotic antiplatelet agent , include follow : Aspirin aspirincontaining combination Clopidogrel Dipyridamole Tirofiban Epoprostenol Eptifibatide Cilostazol Abciximab Ticlopidine Warfarin Lowdose warfarin prophylaxis prevent catheter thrombosis allow Heparin low molecular weight heparin Heparin IV line flush allow At least 7 day since prior concurrent use follow drug : Itraconazole Ketoconazole ( dose &gt; 200 mg/day ) Miconazole Voriconazole Telithromycin Primidone Rifabutin Rifampin St. John 's wort Carbamazepine Oxcarbazepine Rifapentine Phenobarbital Phenytoin Quinidine Procainamide Disopyramide Amiodarone Sotalol Ibutilide Dofetilide Erythromycin Clarithromycin Chlorpromazine Haloperidol Mesoridazine Thioridazine Pimozide Bepridil Droperidol Halofantrine Levomethadyl Sparfloxacin No concurrent H2 blocker proton pump inhibitor No bisphosphonate therapy first 8 week study treatment No concurrent hormone chemotherapeutic agent except steroid administer dasatinibrelated pleural effusion hormone administer nondiseaserelated condition ( e.g. , insulin diabetes ) No concurrent palliative radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>epithelial mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>sarcomatous mesothelioma</keyword>
</DOC>